Sofinnova Partners created Epsilen Bio, a biotechnology company developing transformative therapies for patients affected by underserved medical conditions, through stable and long-lasting epigenetic silencing of genes involved in pathological processes.
Chroma Medicine acquired the company in November, 2021.
Based in Milan, Epsilen Bio was founded in December 2019 by the renowned gene therapy experts Prof. Angelo Lombardo and Prof. Luigi Naldini, The Telethon Foundation and San Raffaele Hospital. Epsilen Bio was a spin-off of SR-Tiget, a world leading cell and gene therapy research institute, and received seed funding from Sofinnova Partners.
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.